Antibody-Mediated LOX-1 Inhibition Post-MI Inflammation
- On may 26, 2023, the Food and Drug Administration (FDA) approved Farxiga (dapagliflozin), manufactured by AstraZeneca, for the treatment of heart failure with preserved ejection fraction (HFpEF).
- Heart failure is a chronic condition where the heart can't pump enough blood to meet the body's needs. HFpEF, accounting for roughly 50% of all heart failure cases,...
- Traditional diagnostic criteria for HFpEF involve echocardiography to assess ejection fraction, along with evaluation of diastolic function.
Okay, I’m ready to transform the provided content into a polished, SEO-optimized article adhering to all specified guidelines. I will focus on creating a complete and informative piece, incorporating the provided ethics disclosures appropriately.
Here’s the HTML5 `
Farxiga (dapagliflozin) Receives FDA Approval for Heart Failure with Preserved Ejection Fraction
what Happened?
On may 26, 2023, the Food and Drug Administration (FDA) approved Farxiga (dapagliflozin), manufactured by AstraZeneca, for the treatment of heart failure with preserved ejection fraction (HFpEF). This marks a critically important advancement in treating a condition that, until recently, lacked effective pharmacological therapies. The approval is based on the results of the DELIVER trial, a landmark study demonstrating Farxiga’s ability to reduce the risk of cardiovascular death and hospitalization for heart failure.
Understanding Heart Failure with Preserved Ejection Fraction
Heart failure is a chronic condition where the heart can’t pump enough blood to meet the body’s needs. HFpEF, accounting for roughly 50% of all heart failure cases, is especially challenging because the heart muscle contracts normally (preserved ejection fraction – typically 50% or higher), but the heart struggles to relax and fill with blood properly. This leads to symptoms like shortness of breath, fatigue, and swelling in the legs and ankles. Historically, treatment focused on managing symptoms, as few medications demonstrably improved outcomes.
Traditional diagnostic criteria for HFpEF involve echocardiography to assess ejection fraction, along with evaluation of diastolic function. However, the diagnosis can be complex, often requiring a combination of clinical assessment, imaging, and biomarker testing (like natriuretic peptides). The prevalence of HFpEF increases with age, obesity, hypertension, and diabetes.
The DELIVER Trial: A Breakthrough in HFpEF Treatment
The DELIVER trial (Dapagliflozin Evaluation to Improve the LIVEs of Patients with Preserved Ejection Fraction Heart Failure) was a pivotal, double-blind, randomized, placebo-controlled trial involving 6,605 participants with hfpef. Published in the New England Journal of Medicine in August 2022, the trial demonstrated that Farxiga reduced the composite outcome of cardiovascular death or hospitalization for heart failure by 22% compared to placebo (hazard ratio 0.78; 95% confidence interval, 0.69 to 0.88; P<0.001).
Key findings from the DELIVER trial:
- Primary Outcome: 22% reduction in cardiovascular death or heart failure hospitalization.
- secondary Outcomes: Significant reductions in hospitalizations for heart failure and urgent heart failure visits.
- Subgroup Analysis: Benefit observed across various subgroups, including patients with and without diabetes.
- Ejection Fraction: The average ejection fraction of participants was 62.2% in the dapagliflozin group and 62.0% in the placebo group.
| Outcome | Dapagliflozin (n=3302) | Placebo (
|
|---|